The top pharmaceutical companies by R&D expenditure
Pharmaceutical Technology
MAY 2, 2024
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
Harm Reduction Therapeutics Begins Shipping OTC Naloxone Nasal Spray
Drug Topics
DECEMBER 21, 2023
The nonprofit pharmaceutical company plans to begin fulfilling orders for RiVive more broadly in early 2023 and will make it available across the US for free of charge or at a low breakeven cost.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Can forecasting help identify market opportunities for pharmaceutical companies?
pharmaphorum
JUNE 19, 2023
Can forecasting help identify market opportunities for pharmaceutical companies? Mike.Hammerton Mon, 19/06/2023 - 08:00 Bookmark this
STAT+: Health care CEOs dialed back their pay in 2023. They still made $3.5 billion
STAT
SEPTEMBER 30, 2024
Health care stocks stumbled compared with the rest of the market in 2023. Companies missed their profit targets. Even in a down year, the median health care CEO made 51 times the median American household income, which was around $81,000 in 2023. Some CEOs even lost their bonuses. million in 2022.
STAT+: Young biotech venture firm raises $500 million for its second fund
STAT
DECEMBER 9, 2024
Well, in Dimension’s case, they end up investing in some buzzy AI startups, counseling pharmaceutical companies, ribbing one another about expense reports, and — as of Monday — are able to raise $500 million for their second fund.
Nine for 2023, part three: thriving or surviving?
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
Guide to Outsourcing 2023
European Pharmaceutical Review
NOVEMBER 14, 2023
Outsourcing regulatory activities in pharma Here, EPR’s Editor explores some key considerations, approaches and strategies for pharmaceutical companies looking to outsource regulatory activities. The post Guide to Outsourcing 2023 appeared first on European Pharmaceutical Review.
ESMO 2023: Janssen reveals data for intravesical delivery system
European Pharmaceutical Review
OCTOBER 23, 2023
Janssen Pharmaceutical Companies of Johnson & Johnson’s data were featured at the European Society for Medical Oncology (ESMO) 2023 Congress. coli vaccine The post ESMO 2023: Janssen reveals data for intravesical delivery system appeared first on European Pharmaceutical Review.
ECNP 2023: new esketamine NS safety data for depression
European Pharmaceutical Review
OCTOBER 10, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson has revealed that according to new safety data, SPRAVATO ® (esketamine nasal spray [NS]) has demonstrated superior efficacy compared to quetiapine extended-release (Quetiapine XR) for treatment-resistant depression (TRD).
AI continues to gain momentum in the biopharmaceutical industry in 2023
Pharmaceutical Technology
JANUARY 16, 2023
One such emerging technology, artificial intelligence (AI), is expected to play an important role in the pharmaceutical sector in 2023. With more pharmaceutical companies tapping into AI technology to enhance the processes within their value chains, AI will continue to evolve over time.
STAT+: AbbVie dramatically outspent its pharma company rivals in 2023 to promote its drugs to doctors
STAT
JULY 5, 2024
WASHINGTON — Pharmaceutical giant AbbVie paid health care providers roughly $145.7 The massive sum spent by AbbVie, the maker of the mega blockbuster anti-inflammatory drug Humira, is the most a pharmaceutical company has spent on marketing to doctors since such data became available in 2017.
Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms
pharmaphorum
JANUARY 16, 2023
The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. Innovation will power the market.
FDA 
98
98 
Why script-to-dispense conversion will take centre stage in 2023
pharmaphorum
JANUARY 6, 2023
In 2023, expect manufacturers to further shift their focus away from acquiring new patient prescriptions to retaining existing customers. So, what can a pharmaceutical company best control that directly affects its bottom line? The post Why script-to-dispense conversion will take centre stage in 2023 appeared first on.
Biden administration flags dozens of pharma companies to pay Medicare rebates for 'outrageous' price hikes
Fierce Healthcare
DECEMBER 14, 2023
The Biden administration is cracking down on pharmaceutical companies as part of its price-fighting measures under the Inflation Reduction Act. | The Biden Administration announced Thursday a list of 48 Part B drugs with prices that rose faster than the rate of inflation in the final quarter of 2023.
Key developments in pharmaceutical manufacturing – September 2023
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. The pharmaceutical company stated it will establish the first industrial-scale supply of biomethane. Which new pharmaceutical manufacturing facility are you most looking forward to being developed and why?
Vaccines 104
104 
Meet the 2023 FOYA Operations Category Winner: WuXi Biologics Ireland Limited
ISPE
AUGUST 30, 2023
WuXi Biologics has almost 600 global partners, including all the top 20 pharmaceutical companies. As of 31 May 2023, WuXi Biologics supports 613 integrated client projects, including 21 in commercial manufacturing. Further works are also in the pipeline including ISO accordion in 2023/2024. Want to Learn More?
Who’s saying what? Cybersecurity mentions in company filings of pharmaceutical industry increased by 113% in Q1 2023
Pharmaceutical Technology
MAY 9, 2023
The global pharmaceutical industry experienced a 113% rise in company filings mentions of cybersecurity in Q1 2023 compared with the previous quarter, with the highest share accounted for by Alnylam Pharmaceuticals with 114% year-on-year increase, according to GlobalData’s analysis of over 667 pharmaceutical company filings.
Pharmaceutical training boost: how the growth and skills levy could shape industry development
European Pharmaceutical Review
FEBRUARY 17, 2025
billion in 2023/24. Under the new Growth and Skills Levy, employers will be able to allocate funds toward a wider range of training initiatives, including modular courses, short-term programmes, and industry-specific certifications, ensuring companies can equip their workforce with the latest skills in a rapidly evolving landscape.
Opinion: Insulin is increasingly affordable in the U.S. What about the rest of the world?
STAT
OCTOBER 24, 2023
Following two decades of sharp increases for consumers, the companies vowed to cut insulin prices for some insulins by at least 70%, meaning many people could see their insulin costs capped at $35 a month in the near future. Sanofi and NovoNordisk will lower their prices as of January 2024; Lilly reduced it to $35 per month in March 2023.)
Who’s saying what? Cybersecurity mentions in company filings of pharmaceutical industry increased by 113% in Q1 2023
Pharmaceutical Technology
MAY 9, 2023
The global pharmaceutical industry experienced a 113% rise in company filings mentions of cybersecurity in Q1 2023 compared with the previous quarter, with the highest share accounted for by Alnylam Pharmaceuticals with 114% year-on-year increase, according to GlobalData’s analysis of over 667 pharmaceutical company filings.
Pumping the unemployed with weight-loss drugs echoes Victorian attitudes to the poor | Kenan Malik
The Guardian - Pharmaceutical Industry
OCTOBER 19, 2024
Shifting blame to the victims of economic policy is an old trick by politicians.
Documentation 111
111 
EU Urban Wastewater Treatment Directive may compromise EU medicine availability
European Pharmaceutical Review
FEBRUARY 13, 2025
Based on the new cost estimates, pharmaceutical manufacturers in Finland alone will be required to fund 280816 million of these expenses, The directive , enforced on 1 January 2025, imposes an extended manufacturer responsibility on the removal of micro-pollutants from wastewaters.
Interview questions and answers for pharmaceutical analyst post
Pharma Tutor
APRIL 4, 2023
Interview questions and answers for pharmaceutical analyst post admin Tue, 04/04/2023 - 16:13 A pharmaceutical analyst is a professional who works in the pharmaceutical industry and is responsible for performing various tests and analyses on drugs and drug products.
We like to think UK health services aren’t influenced by big money. That’s just not true | Margaret McCartney
The Guardian - Pharmaceutical Industry
AUGUST 28, 2024
There must be transparency over funding to medics from the pharmaceutical industry – and that’s only the start Shouldn’t we be able to trust doctors to give us independent advice? This is just one of many monetary exchanges between the pharmaceutical industry and medics. The payment was to promote a flu vaccine, not the Covid vaccine.
Vaccines 111
111 
Janssen rebrands its identity
European Pharmaceutical Review
SEPTEMBER 15, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson has changed its name to Johnson & Johnson Innovative Medicine (J&J Innovative Medicine). This new re-brand for the company follows the appointment its new Executive Vice President, Pharmaceuticals, R&D, an ex- Sanofi executive, in February 2023.
Chemotherapy 98
98 
STAT+: Pharmalittle: We’re reading about the FDA listing Novo drugs as ‘available,’ pharma layoffs, and more
STAT
OCTOBER 31, 2024
pharmaceutical industry fell last month, although the number of job cuts remains well above what was seen at the same time in 2023, according to Challenger, Gray & Christmas, the outplacement and executive coaching firm. This was also well below the 1,624 jobs the industry slashed in October 2023.
Who’s saying what? Environmental sustainability mentions in company filings of pharmaceutical industry increased by 114% in Q1 2023
Pharmaceutical Technology
MAY 9, 2023
The global pharmaceutical industry experienced a 114% rise in company filings mentions of environmental sustainability in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novozymes with 27% year-on-year increase, according to GlobalData’s analysis of over 757 pharmaceutical company filings.
Who’s saying what? Big Data mentions in company filings of pharmaceutical industry decreased by 13% in Q1 2023
Pharmaceutical Technology
MAY 29, 2023
The global pharmaceutical industry experienced a 13% drop in company filings mentions of big data in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novartis with 185% year-on-year increase, according to GlobalData’s analysis of over 603 pharmaceutical company filings.
Who’s saying what? Artificial Intelligence mentions in company filings of pharmaceutical industry increased by 190% in Q1 2023
Pharmaceutical Technology
MAY 9, 2023
The global pharmaceutical industry experienced a 190% rise in company filings mentions of artificial intelligence in Q1 2023 compared with the previous quarter, with the highest share accounted for by Novartis with 59% year-on-year increase, according to GlobalData’s analysis of over 220 pharmaceutical company filings.
Who’s innovating where? Environmental sustainability related patent filings activity decreased by 23% in the pharmaceutical industry in Q1 2023
Pharmaceutical Technology
MAY 23, 2023
The global pharmaceutical industry experienced a 23% decline in the number of environmental sustainability-related patent applications in Q1 2023 compared with the previous quarter. The total number of environmental sustainability-related grants dropped by 24% in Q1 2023, according to GlobalData’s Patent Analytics. in Q1 2023.
Curbing AMR through sustainable antibiotic manufacturing
European Pharmaceutical Review
AUGUST 31, 2023
[pharmaceutical companies] must take measures to manage antibiotic waste across the manufacturing supply chain” 2023 has so far, delivered a spectrum of change for antibiotic manufacturers across the pharmaceutical industry, from supply chain issues through to regulatory opportunities.
Humira generic availability, cost, and dosage
The Checkup by Singlecare
MARCH 8, 2024
It was FDA approved in 2016 and became available in the United States in January 2023. The pharmaceutical company that makes Amjevita is called Amgen, Inc. It was FDA approved in August 2017 as a biosimilar, approved in 2021 as an interchangeable biosimilar, and became available in the United States in July of 2023.
Dosage 97
97 
Technology innovation aiding process spectroscopy market growth
European Pharmaceutical Review
JUNE 3, 2024
Innovations in the process spectroscopy market molecular spectroscopy accounted for the greatest share of the process spectroscopy market between 2023 to 2033″ The analysis found that molecular spectroscopy accounted for the greatest share of the process spectroscopy market between the 2023 to 2033 forecast period.
STAT+: Pharmalittle: We’re reading about China detaining AstraZeneca staff, pharma layoffs, and more
STAT
SEPTEMBER 5, 2024
pharmaceutical industry surged last month, boosting the year-to-date job cuts well above what was seen at the same time in 2023, according to Challenger, Gray & Christmas, the outplacement and executive coaching firm. This was also well above the 783 jobs the industry slashed in August 2023.
Packaging 101
101 
Boehringer Ingelheim to advance bacterial cancer therapeutics
European Pharmaceutical Review
NOVEMBER 23, 2023
Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. The immuno-oncology therapeutic market In analysis published by GlobalData in July 2023, immuno-oncology therapies have emerged as a novel treatment category.
Europe’s pharmaceutical packaging market to value over $35bn by 2028
European Pharmaceutical Review
OCTOBER 24, 2023
Based on end-user segmentation, the market report on Europe’s pharmaceutical packaging market stated that the pharmaceutical companies segment accounted for the highest share of 45.99 percent between the forecast period: 2023 and 2028. percent between the forecast period 2023-2028. percent in 2022.
Packaging 118
118 
Chemo-free regimen demonstrates efficacy in NSCLC
European Pharmaceutical Review
SEPTEMBER 29, 2023
Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).
PDA revises report on glass container manufacturing
European Pharmaceutical Review
JULY 5, 2023
Revised for 2023, the Parenteral Drug Association (PDA) has published an update to its Technical Report No. 43: Identification and Classification of Nonconformities in Moulded and Tubular Glass Containers for Pharmaceutical Manufacturing.
Packaging 96
96 
Pharmaceutical excipients market to witness expansion
European Pharmaceutical Review
DECEMBER 4, 2023
A report published by MarketsandMarkets has estimated that the pharmaceutical excipients market will value $14.9 percent between 2023 to 2028. This is compared to the expected revenue for the market in 2023 reaching $10.7 ” In October 2023, one of the winners of the 2023 CPHI Pharma Award was Lubrizol Life Science Health.
Sales soar at Danish firm behind weight-loss drug semaglutide
The Guardian - Pharmaceutical Industry
NOVEMBER 2, 2023
Novo Nordisk says it struggling to keep up with demand after becoming Europe’s most valuable company Business live – latest updates The maker of blockbuster weight-loss drug semaglutide has reported a steep rise in sales and profits as health systems around the world rush to use it to tackle obesity. Continue reading.
Who’s saying what? Cloud mentions in company filings of pharmaceutical industry increased by 149% in Q1 2023
Pharmaceutical Technology
JUNE 12, 2023
The global pharmaceutical industry experienced a 149% rise in company filings mentions of cloud in Q1 2023 compared with the previous quarter, with the highest share accounted for by Pfizer with 14% year-on-year decrease, according to GlobalData’s analysis of over 140 pharmaceutical company filings.
Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023
Pharmaceutical Technology
MAY 29, 2023
The global pharmaceutical industry experienced a 17% rise in company filings mentions of blockchain in Q1 2023 compared with the previous quarter, with the highest share accounted for by Bayer, according to GlobalData’s analysis of over 60 pharmaceutical company filings.
Who’s saying what? Corporate governance mentions in company filings of pharmaceutical industry increased by 141% in Q1 2023
Pharmaceutical Technology
MAY 9, 2023
The global pharmaceutical industry experienced a 141% rise in company filings mentions of corporate governance in Q1 2023 compared with the previous quarter, with the highest share accounted for by GSK with 306% year-on-year increase, according to GlobalData’s analysis of over 898 pharmaceutical company filings.
Who’s saying what? Internet of Things mentions in company filings of pharmaceutical industry increased by 120% in Q1 2023
Pharmaceutical Technology
JUNE 12, 2023
The global pharmaceutical industry experienced a 120% rise in company filings mentions of internet of things in Q1 2023 compared with the previous quarter, with the highest share accounted for by Moderna, according to GlobalData’s analysis of over 61 pharmaceutical company filings.
Let's personalize your content